ACKERMANS V.HAAREN 284.800 € (-0,77 %) AB INBEV 74.680 € (+1,22 %) ARGENX SE 784.400 € (+0,33 %) UMICORE 20.820 € (-2,25 %) VASTNED 29.750 € (+0,34 %) KBC ANCORA 80.900 € (+0,62 %) IBA 16.760 € (+0,60 %) KBC 117.250 € (-0,51 %) ELIA GROUP 138.500 € (-0,86 %) WDP 22.520 € (+1,08 %) HOME INVEST BE. 19.300 € (-0,21 %) AZELIS GROUP 9.910 € (-0,10 %) EVS 27.700 € (-0,72 %) WHAT'S COOKING GP 144.500 € (0,00 %) SYENSQO 66.800 € (-0,30 %) BPOST 1.552 € (-0,51 %) TITAN S.A. 52.500 € (-1,50 %) MONTEA 67.200 € (+1,66 %) MELEXIS 76.400 € (-3,41 %) GIMV 45.150 € (+2,03 %) SHURGARD 25.750 € (+0,98 %) CENERGY 23.300 € (-3,80 %) KINEPOLIS GROUP 36.500 € (+2,38 %) JENSEN-GROUP 84.200 € (+1,45 %) ORANGE BELGIUM 21.500 € (0,00 %) SIPEF 92.900 € (+0,32 %) CIE BOIS SAUVAGE 302.000 € (0,00 %) FLUXYS BELGIUM D 19.500 € (+0,26 %) RETAIL ESTATES 70.100 € (+0,43 %) ATENOR 1.690 € (-3,43 %) FAGRON 23.800 € (-0,63 %) ACCENTIS 0.026 € (-1,89 %) BEKAERT 39.500 € (-1,86 %) XIOR 26.700 € (+1,14 %) WERELDHAVE BELGIUM 52.800 € (+0,76 %) PROXIMUS 6.085 € (-0,33 %) D'IETEREN GROUP 170.500 € (-1,73 %) TINC 11.380 € (0,00 %) SOFINA 220.200 € (+0,46 %) ONWARD MEDICAL 2.640 € (+0,96 %) ECONOCOM GROUP 1.515 € (+1,68 %) GBL 78.950 € (-0,19 %) RECTICEL 10.740 € (-1,10 %) NYXOAH 1.530 € (+3,66 %) AGEAS 69.750 € (+0,50 %) AGFA-GEVAERT 0.423 € (-1,40 %) COFINIMMO 84.500 € (+1,62 %) CARE PROPERTY INV. 12.600 € (+0,48 %) LOTUS BAKERIES 11 520.000 € (+0,88 %) VGP 84.300 € (0,00 %) VIOHALCO 19.320 € (-0,92 %) BIOTALYS 3.120 € (-1,58 %) ONTEX GROUP 2.525 € (+0,20 %) TUBIZE-FIN 225.400 € (+2,55 %) VAN DE VELDE 30.200 € (0,00 %) CAMPINE 218.000 € (+1,87 %) CMB.TECH 12.500 € (-4,87 %) DECEUNINCK 2.220 € (0,00 %) CELYAD ONCOLOGY 0.251 € (+0,40 %) BREDERODE 104.600 € (+1,36 %)
NANOBIOTIX 31.080 € (+3,74 %)
SERGEFERRARI GROUP 8.000 € (+2,56 %)
TOTALENERGIES 68.360 € (-1,31 %)
SERGEFERRARI GROUP 8.000 € (+2,56 %)
ADYEN 824.900 € (+0,37 %)
EXAIL TECHNOLOGIES 116.700 € (+25,28 %)
CAPGEMINI 89.680 € (+1,33 %)
SHELL PLC 33.700 € (-1,00 %)
BUREAU VERITAS 26.120 € (+0,66 %)
HERMES INTL 1 626.000 € (+0,77 %)
PHILIPS KON 23.890 € (-0,17 %)
SANOFI 75.070 € (+1,78 %)
ASML HOLDING 1 578.200 € (-0,99 %)
BOLLORE 4.100 € (+0,15 %)
VEOLIA ENVIRON. 36.230 € (+0,22 %)
SMCP 5.015 € (+0,30 %)
FLOW TRADERS 25.580 € (-0,93 %)
ASM INTERNATIONAL 948.000 € (-4,34 %)
AYVENS 11.460 € (-0,87 %)
CSG 12.682 € (+2,69 %)
BE SEMICONDUCTOR 282.700 € (-2,21 %)
SCOR SE 31.980 € (+0,50 %)
STMICROELECTRONICS 62.580 € (-3,81 %)
ESSILORLUXOTTICA 168.650 € (+1,54 %)
CRCAM TOURAINE CCI 138.500 € (-0,93 %)
LISI 66.100 € (-0,15 %)
LVMH 495.750 € (+0,27 %)
BOUYGUES 49.750 € (-0,78 %)
DSM FIRMENICH AG 79.980 € (-0,65 %)
NEXANS 141.100 € (-3,75 %)
STELLANTIS NV 5.024 € (-1,95 %)
THALES 216.500 € (-0,87 %)
UMG 18.355 € (+0,71 %)
NN GROUP 76.320 € (-0,29 %)
AHOLD DEL 35.430 € (+0,85 %)
2CRSI 27.520 € (+8,01 %)
SODEXO 51.250 € (-0,10 %)
SOITEC 114.350 € (+1,87 %)
TKH GROUP 43.620 € (+1,73 %)
LNA SANTE 34.000 € (+3,03 %)
OVH 13.600 € (+1,49 %)
BAM GROEP KON 12.550 € (-1,18 %)
AMG 32.900 € (-1,56 %)
EUROFINS SCIENT. 68.960 € (+1,00 %)
AALBERTS NV 38.980 € (-1,66 %)
CEGEDIM 11.040 € (-1,43 %)
DANONE 72.120 € (+3,06 %)
ALSTOM 15.380 € (-1,94 %)
REXEL 36.860 € (-1,18 %)
RELX 27.440 € (-0,29 %)
HAFFNER ENERGY 0.217 € (-2,25 %)
ERAMET 45.160 € (-1,40 %)
SAINT GOBAIN 80.600 € (-1,42 %)
BNP PARIBAS ACT.A 101.120 € (-1,83 %)
RUBIS 31.540 € (+0,64 %)
JCDECAUX 19.050 € (+1,33 %)
PERNOD RICARD 65.960 € (-0,06 %)
SAVENCIA 66.600 € (0,00 %)
AIRBUS 191.900 € (-1,63 %)
ALTEN 53.400 € (+1,81 %) News Réglementées
|
19/06/2026 15:15
Original-Research: Electro Optic Systems Holdings Ltd. (von Montega AG): BuyOriginal-Research: Electro Optic Systems Holdings Ltd. - from Montega AG Classification of Montega AG to Electro Optic Systems Holdings Ltd.
Laser JV, RWS order and BAE partnership support growth trajectory EOS has released a series of positive announcements over recent days, highlighting continued momentum across its core growth pillars. Key developments include a new AUD 175m Slinger counter-drone order and a strategic joint venture with UAE-based Gen5 to accelerate HELW development and production, the selection of MARSS as C2 provider for BAE Systems, as well as a revenue guidance for the standalone EOS business. Major Slinger order and transformational HELW joint venture: EOS announced the award of an AUD 175m Slinger counter-drone order from UAE-based Gen5. The systems are expected to be manufactured in both Australia and the UAE, with deliveries scheduled for 2027 and 2028. Beyond the immediate order value, we view the transaction as further evidence of EOS’ growing strategic importance in the Middle East, where demand for counter-drone systems continues to increase rapidly after the recent regional tensions. Even more strategically important, in our view, is the accompanying joint venture agreement between EOS and Gen5. The proposed JV aims to develop a next-generation 200-300kW High Energy Laser Weapon, while simultaneously localising production of EOS’ existing 100-150kW laser systems and selected RWS products for the UAE and wider MENA region. Importantly, the agreement includes targets to secure a minimum USD 250m for the development of a 200-300kW HELW product family and a further minimum USD 290m order for several 100kW HELW systems. While these contracts are not guaranteed, the framework highlights the substantial commercial upside emerging from EOS’ laser business and reinforces its already strong competitive positioning. It effectively unlocks the ballistic missile defence domain for EOS and would represent the only commercial ~300kW HELW platform outside classified US defence prime programmes. Overall, this further strengthens conviction in the long-term growth potential of the segment. BAE Systems partnership validates MARSS technology: A further important milestone was the selection of MARSS as Command-and-Control provider for BAE Systems’ Anti-Threat System (BATS). Under the agreement, MARSS’ NiDAR platform will serve as the central command architecture integrating sensors and effectors across BAE’s counterdrone offering. The partnership represents an important validation of MARSS’ technology by one of the world's leading defence contractors and highlights the battle proven competitive positioning of NiDAR as an advanced C2 platform. Guidance supports forecast upgrades: Alongside the operational updates, EOS provided its first revenue outlook for the standalone EOS business excluding MARSS. Based solely on existing contracted orders, management expects FY 2026 revenue of AUD 240m-270m, while emphasising that this figure excludes any contribution from MARSS and any future contract wins. Given the continued strength of order intake, the growing visibility provided by the backlog and the increasing contribution from recently secured contracts, we are raising our forecasts for FY 2026 and beyond. We now expect group revenue (including MARSS) to approach AUD 300m in FY 2026, followed by continued medium double-digit percentage growth over the subsequent two years. In our view, the current backlog, combined with the substantial opportunity pipeline in laser systems, counter-drone solutions and command-and-control architectures, provides a strong foundation for this growth trajectory. Conclusion: The recent announcements further strengthen our positive investment case for EOS. The combination of rising global demand for counter-drone systems, growing traction in laser weapons, increasing penetration of the strategically important Middle Eastern market and the successful integration of MARSS continues to support the company's evolution into a leading defence technology provider. Importantly, the newly announced HELW joint venture demonstrates that EOS is beginning to convert its technological leadership in directed-energy weapons into concrete commercial opportunities. Combined with increasing order momentum and improving revenue visibility, we see further upside potential for both earnings and valuation. Following the stronger-than-expected operational developments, improved backlog visibility and increased growth potential from MARSS, RWS and HELW, we raise our price target from AUD 16.00 to AUD 18.00 per share and reiterate our Buy rating. +++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Bitte lesen Sie unseren RISIKOHINWEIS / HAFTUNGSAUSSCHLUSS unter http://www.montega.de +++ Über Montega: Die Montega AG ist eine innovative Investment-Banking-Boutique mit klarem Fokus auf den Mittelstand und agiert als Plattformanbieter für den Austausch zwischen börsennotierten Unternehmen und institutionellen Investoren. Montega erstellt hochwertiges Equity Research, veranstaltet vielfältige Kapitalmarktevents im In- und Ausland und bietet eine umfassende Unterstützung bei Eigen- und Fremdkapitalfinanzierungen. Die Mission: Emittenten und Investoren zusammenbringen und für Transparenz im Börsenumfeld sorgen. Dabei konzentriert sich Montega auf jene Marktteilnehmer, deren Sprache die Mittelstandsexperten am besten beherrschen: Small- und MidCaps auf der einen sowie Vermögensverwalter, Family Offices und Investment-Boutiquen mit einem Anlagefokus im Nebenwertebereich auf der anderen Seite. You can download the research here: Factsheet Contact for questions: Montega AG - Equity Research Tel.: +49 (0)40 41111 37-80 Web: www.montega.de E-Mail: info@montega.de LinkedIn: https://www.linkedin.com/company/montega-ag The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 2350224 19.06.2026 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||
© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière